McKesson 1Q Revenue Rises 8%; Lifts Adj EPS Outlook

Dow Jones04:43

McKesson posted higher revenue in its fiscal first quarter, helped by increased prescription volumes and distribution of specialty products, and raised its adjusted earnings outlook for the year.

The Irving, Texas-based pharmaceutical distributor on Wednesday reported a profit of $614 million, or $5.15 a share, compared with $784 million, or $6.25 a share, in the same quarter a year earlier.

Adjusted earnings were $9.93 a share. Analysts polled by FactSet expected $9.56 a share.

Revenue rose to 8% to $105.38 billion, ahead of the $103.88 billion expected by analysts.

The company's profit slipped primarily due to a redemption value adjustment of $293 million, which was related to redeemable non-controlling interests for the medical-surgical solutions segment, which it sold a minority interest to Apollo affiliates for $1.25 billion in June.

Its revenue rose 5% in its North American pharmaceutical segment, its largest, primarily due to higher prescription volume. Revenue rose 33% in its oncology and multispecialty segment, 9% in its prescription technology solutions segment and 4% in its medical-surgical solutions segment.

The company now expects adjusted per-share earnings between $44.20 and $45, up from its prior range of $43.80 to $44.60.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2657575939?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 04:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657575939","market":"hk","top_or_hot":-1,"title":"McKesson 1Q Revenue Rises 8%; Lifts Adj EPS Outlook","media":"Dow Jones","content":"<html><head></head><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\"> \n</pre>\n<p>\n  McKesson posted higher revenue in its fiscal first quarter, helped by increased prescription volumes and distribution of specialty products, and raised its adjusted earnings outlook for the year. \n</p>\n<p>\n  The Irving, Texas-based pharmaceutical distributor on Wednesday reported a profit of $614 million, or $5.15 a share, compared with $784 million, or $6.25 a share, in the same quarter a year earlier. \n</p>\n<p>\n  Adjusted earnings were $9.93 a share. Analysts polled by FactSet expected $9.56 a share. \n</p>\n<p>\n  Revenue rose to 8% to $105.38 billion, ahead of the $103.88 billion expected by analysts. \n</p>\n<p>\n  The company&#39;s profit slipped primarily due to a redemption value adjustment of $293 million, which was related to redeemable non-controlling interests for the medical-surgical solutions segment, which it sold a minority interest to Apollo affiliates for $1.25 billion in June. \n</p>\n<p>\n  Its revenue rose 5% in its <a href=\"https://laohu8.com/S/FNCSF\">North American</a> pharmaceutical segment, its largest, primarily due to higher prescription volume. Revenue rose 33% in its oncology and multispecialty segment, 9% in its prescription technology solutions segment and 4% in its medical-surgical solutions segment. \n</p>\n<p>\n  The company now expects adjusted per-share earnings between $44.20 and $45, up from its prior range of $43.80 to $44.60. \n</p>\n<pre style=\"white-space: pre\"> \n</pre>\n<pre style=\"white-space: pre\"> \n</pre>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>McKesson 1Q Revenue Rises 8%; Lifts Adj EPS Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMcKesson 1Q Revenue Rises 8%; Lifts Adj EPS Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-06 04:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\"> \n</pre>\n<p>\n  McKesson posted higher revenue in its fiscal first quarter, helped by increased prescription volumes and distribution of specialty products, and raised its adjusted earnings outlook for the year. \n</p>\n<p>\n  The Irving, Texas-based pharmaceutical distributor on Wednesday reported a profit of $614 million, or $5.15 a share, compared with $784 million, or $6.25 a share, in the same quarter a year earlier. \n</p>\n<p>\n  Adjusted earnings were $9.93 a share. Analysts polled by FactSet expected $9.56 a share. \n</p>\n<p>\n  Revenue rose to 8% to $105.38 billion, ahead of the $103.88 billion expected by analysts. \n</p>\n<p>\n  The company&#39;s profit slipped primarily due to a redemption value adjustment of $293 million, which was related to redeemable non-controlling interests for the medical-surgical solutions segment, which it sold a minority interest to Apollo affiliates for $1.25 billion in June. \n</p>\n<p>\n  Its revenue rose 5% in its <a href=\"https://laohu8.com/S/FNCSF\">North American</a> pharmaceutical segment, its largest, primarily due to higher prescription volume. Revenue rose 33% in its oncology and multispecialty segment, 9% in its prescription technology solutions segment and 4% in its medical-surgical solutions segment. \n</p>\n<p>\n  The company now expects adjusted per-share earnings between $44.20 and $45, up from its prior range of $43.80 to $44.60. \n</p>\n<pre style=\"white-space: pre\"> \n</pre>\n<pre style=\"white-space: pre\"> \n</pre>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2657575939","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657575939","pubTimestamp":1785962580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"McKesson posted higher revenue in its fiscal first quarter, helped by increased prescription volumes and distribution of specialty products, and raised its adjusted earnings outlook for the year.The Irving, Texas-based pharmaceutical distributor on Wednesday reported a profit of $614 million, or $5.15 a share, compared with $784 million, or $6.25 a share, in the same quarter a year earlier.Adjusted earnings were $9.93 a share. Analysts polled by FactSet expected $9.56 a share.Revenue rose to 8% to $105.38 billion, ahead of the $103.88 billion expected by analysts.The company's profit slipped primarily due to a redemption value adjustment of $293 million, which was related to redeemable non-controlling interests for the medical-surgical solutions segment, which it sold a minority interest to Apollo affiliates for $1.25 billion in June.Its revenue rose 5% in its North American pharmaceutical segment, its largest, primarily due to higher prescription volume. Revenue rose 33% in its oncolo","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"McKesson 第一季度收入增长 8%；提升调整每股收益前景","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/4e49f0a5a12d9d6b5afc3a0791f7289a","symbols_score_info":{"MCK":1.5},"content_text":"McKesson posted higher revenue in its fiscal first quarter, helped by increased prescription volumes and distribution of specialty products, and raised its adjusted earnings outlook for the year. \n\n\n  The Irving, Texas-based pharmaceutical distributor on Wednesday reported a profit of $614 million, or $5.15 a share, compared with $784 million, or $6.25 a share, in the same quarter a year earlier. \n\n\n  Adjusted earnings were $9.93 a share. Analysts polled by FactSet expected $9.56 a share. \n\n\n  Revenue rose to 8% to $105.38 billion, ahead of the $103.88 billion expected by analysts. \n\n\n  The company's profit slipped primarily due to a redemption value adjustment of $293 million, which was related to redeemable non-controlling interests for the medical-surgical solutions segment, which it sold a minority interest to Apollo affiliates for $1.25 billion in June. \n\n\n  Its revenue rose 5% in its North American pharmaceutical segment, its largest, primarily due to higher prescription volume. Revenue rose 33% in its oncology and multispecialty segment, 9% in its prescription technology solutions segment and 4% in its medical-surgical solutions segment. \n\n\n  The company now expects adjusted per-share earnings between $44.20 and $45, up from its prior range of $43.80 to $44.60.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657575939","isCrawlerRequest":true}